In the Chinese mainland, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are twelve approved indications for ...

Capricor Therapeutics Second Quarter 2025 Financial Results and Recent Corporate Update Conference Call and Webcast Participants can use the guest dial-in numbers above and be answered by an operator, ...

The offering includes participation from new and existing investors, including Commodore Capital, Blackstone Multi-Asset Investing, Farallon Capital Management, L.L.C., Janus Henderson Investors, RA ...

Loss (gain) on Fair Value Remeasurement of Contingent Consideration: For the quarter ended June 30, 2025, the loss on fair value remeasurement of contingent consideration, in connection with the ...

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...

Week 96 data presented during a late-breaking oral session at EASL 2025 demonstrated the potential of EFX 50mg to reverse cirrhosis in high-need MASH subgroups, including patients with cryptogenic ...

The live webcast of the fireside chat may be accessed from the Investors section of Tenaya’s website. An archived replay will be available on the Tenaya website for approximately 30 days following the ...

Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the ...

Broader Access to Investors: Many institutional investors and life sciences funds are restricted from investing in OTC-listed stocks or those trading below $1. Likewise, some brokerage platforms limit ...

Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain ...

FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the ...

SERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditions ...